We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+9.6%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$961M
AUM Growth
+$50.3M
Cap. Flow
+$3.74M
Cap. Flow %
0.39%
Top 10 Hldgs %
89.37%
Holding
26
New
1
Increased
5
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$8.44M
2
CABA icon
Cabaletta Bio
CABA
+$6.43M
3
XLO icon
Xilio Therapeutics
XLO
+$685K
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$594K
5
ANNX icon
Annexon
ANNX
+$3.2K

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$9.59M
2
TNGX icon
Tango Therapeutics
TNGX
+$1.72M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
26
Arcutis Biotherapeutics
ARQT
$3.3B
– –
-1,030,703
Closed -$9.59M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q3 2024 Portfolio in Review

As of Q3 2024, Bain Capital Life Sciences Investors held 26 positions worth $961M, up 5.5% from $911M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Bain Capital Life Sciences Investors's Q3 2024 filing shows 1 new, 5 increased, 1 reduced and 2 closed positions. Its largest new stake was Cidara Therapeutics: 703,080 shares worth $7.56M. The largest sale was Arcutis Biotherapeutics, an estimated $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Bain Capital Life Sciences Investors's largest Q3 2024 buy was Cidara Therapeutics: 703,080 shares worth $7.56M.
  • Bain Capital Life Sciences Investors added most to Cabaletta Bio in Q3 2024, an estimated $6.43M increase.
  • Bain Capital Life Sciences Investors's biggest Q3 2024 reduction was Tango Therapeutics, cutting an estimated $1.72M.
  • Bain Capital Life Sciences Investors fully exited Arcutis Biotherapeutics in Q3 2024, selling an estimated $9.59M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 89% of its $961M portfolio in Q3 2024.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 2 in Q3 2024.
  • Bain Capital Life Sciences Investors's portfolio value rose 5.5% quarter-over-quarter to $961M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2024, filed 14 Nov 2024.